Floatz logo

Carboplatin

Peritoneal Neoplasm

Eli Lilly and CompanySmall moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Peritoneal Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
Eli Lilly and Company
Phase 3BBB
Oxaliplatin
Sun Yat-sen University
Phase 2/3BB
Patupilone
Novartis Pharmaceuticals
Phase 3BB
Fluorouracilum
AstraZeneca
Phase 2BB
Nogitecan
Eli Lilly and Company
Phase 3BB

View all 44 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaActive
A
Indicative · Phase 4
80 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
non-small cell squamous lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →